

NAMS

News



Arrive Early for Pre-Meeting Symposium

An exciting half-day pre-meeting symposium addresses “Depressive Symptoms and Cognitive Complaints in the Menopausal Transition.” Arrive on Tuesday, September 29 for the symposium that’s scheduled for 8:00 AM to 1:50 PM on Wednesday, September 30. Separate registration from the Annual Meeting is required. For more, go to www.menopause.org/meetings/sciprogramintro.aspx.

Register Now for Annual Meeting

Registration is now open for the 20th NAMS Annual Meeting, scheduled for September 30–October 3 in San Diego, California. The *Program*, registration details, and hotel reservation information are posted on the NAMS Web site (www.menopause.org/meetings/2009HCP.aspx).

NAMS Central Office

The North American Menopause Society
5900 Landerbrook Drive, Suite 390
Mayfield Heights, OH 44124

Mailing Address:

Post Office Box 94527 • Cleveland, OH 44101-4527

Phone: 440/442-7550 • *Fax:* 440/442-2660

E-mail Address: info@menopause.org

Web Site: <http://www.menopause.org>

This year’s meeting offers clinically relevant sessions addressing sexual function, breast cancer, hot flashes, vaginal and vulvar health, osteoporosis, urinary disorders, autoimmune disorders, HT, SERMs, and more—plus practice-related sessions such as how to improve your menopause management business. And the 35 roundtable sessions give you a special opportunity to have your questions addressed. Don’t miss this year’s meeting!

Learn More about SERMs through EMPREss

NAMS, along with Penn State Medical College and Indicia Medical Education, now offers a new provider education initiative called “EMPREss: Enhancing Menopause management through understanding the Physiology of Receptors of Estrogen,” consisting of case consults, an interactive estrogen receptor (ER) challenge, and news summaries focused on integrating menopause-related patient care with a better understanding of the mechanisms and effects of estrogen and other ER ligands such as selective estrogen-receptor modulators (SERMs). Take a look at the first CME component of this initiative, Multiperspective Case Consult #1, in which an OB/GYN, an internist, and an endocrinologist comment on a single patient with severe symptoms. Go to www.menopause.org/empress.aspx.

Future NAMS Annual Meetings

20th NAMS Annual Meeting

September 30–October 3, 2009 • San Diego, CA

21st NAMS Annual Meeting

October 6–9, 2010 • Chicago, IL

22nd NAMS Annual Meeting

September 21–24, 2011 • Washington, DC

23rd NAMS Annual Meeting

October 3–6, 2012 • Orlando, FL

24th NAMS Annual Meeting

October 9–12, 2013 • Dallas, TX

Pay Tribute to Dr. Utian and His Work

Dr. Wulf Utian, NAMS Founder and Executive Director, retires from NAMS at year's end. Pay tribute to his work by attending one or more of the three tribute events: the September 30 session (4:40-6:15 PM) at the San Diego Annual Meeting and two October 24 Cleveland events—a morning Consumer Education Event and a Gala “Tribute to Wulf Utian” that evening. For more, go to www.menopause.org/WUtribute.aspx.



ADVERTISERS' INDEX

Doctors of the World 13

Eli Lilly & Co.

 Evista IFC, 1-4

Novo Nordisk Pharmaceuticals, Inc.

 Vagifem IBC, OBC

Ther-Rx Corporation

 Evamist 9-11

Cardiovascular Corner

(continued from page 28)

management of menopausal symptoms in younger women at low absolute risk for adverse cardiovascular outcomes.¹⁶ ■

JoAnn E. Manson, MD, DrPH, is Professor of Medicine and the Elizabeth F. Brigham Professor of Women's Health, Harvard Medical School; and Chief, Division of Preventive Medicine, Brigham and Women's Hospital. Shari S. Bassuk, ScD, is an Epidemiologist, Division of Preventive Medicine, Brigham and Women's Hospital, Boston, MA.

Dr. Manson and Dr. Bassuk report no potential conflicts related to the content of this article.

References

1. Heiss G, Wallace R, Anderson GL, et al. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. *JAMA* 2008;299:1036-45.
2. Ockene JK, Barad DH, Cochrane BB, et al. Symptom experience after discontinuing use of estrogen plus progestin. *JAMA* 2005;294:183-93.
3. US Preventive Services Task Force. Hormone therapy for the prevention of chronic conditions in postmenopausal women: recommendations from the U.S. Preventive Services Task Force. *Ann Intern Med* 2005; 142:855-60.
4. American College of Obstetricians and Gynecologists. ACOG committee opinion No. 420, November 2008: hormone therapy and heart disease. *Obstet Gynecol* 2008;112:1189-92.
5. Wathen CN, Feig DS, Feightner JW, et al. Hormone replacement therapy for the primary prevention of chronic diseases: recommendation statement from the Canadian Task Force on Preventive Health Care. *CMAJ* 2004;170:1535-37.
6. Utian WH, Archer DF, Bachmann GA, et al. Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society. *Menopause* 2008;15:584-602.
7. Practice Committee of the American Society for Reproductive Medicine. Estrogen and progestogen therapy in postmenopausal women. *Fertil Steril* 2008;90:S88-S102.
8. Samelson EJ, Zhang Y, Kiel DP, et al. Effect of birth cohort on risk of hip fracture: age-specific incidence rates in the Framingham Study. *Am J Public Health* 2002;92:858-62.
9. Manson JE, Bassuk SS. Invited commentary. Hormone therapy and risk of coronary heart disease: why renew the focus on the early years of menopause? *Am J Epidemiol* 2007;166:511-17.
10. Bray PF, Larson JC, Lacroix AZ, et al. Usefulness of baseline lipids and C-reactive protein in women receiving menopausal hormone therapy as predictors of treatment-related coronary events. *Am J Cardiol* 2008; 101:1599-1605.
11. Rossouw JE, Prentice RL, Manson JE, et al. Effects of postmenopausal hormone therapy on cardiovascular disease by age and years since menopause. *JAMA* 2007;297:1465-77.
12. Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. *Circulation* 2007;115:840-5.
13. Liu B, Beral V, Balkwill A, et al. Gallbladder disease and use of transdermal versus oral hormone replacement therapy in postmenopausal women: prospective cohort study. *BMJ* 2008;337:a386.
14. Grodstein F, Manson JE, Stampfer MJ, Rexrode K. Postmenopausal hormone therapy and stroke: role of time since menopause and age at initiation of hormone therapy. *Arch Intern Med* 2008;168:861-6.
15. Endocrine Society. Bioidentical hormones: position statement, October 2006. Available at: http://www.endo-society.org/advocacy/policy/upload/BH_Position_Statement_final_10_25_06_w_Header.pdf (Accessed July 22, 2009.)
16. Manson JE, Bassuk SS. Hot flashes, hormones & your health. New York: McGraw-Hill, 2007.